Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.22.4
Licensing and Other Arrangements - Takeda (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Nov. 16, 2020
Nov. 01, 2006
Feb. 28, 2009
Dec. 31, 2022
Dec. 31, 2021
Licensing and other arrangements          
Revenue from contracts with customers       $ 4,150 $ 36,518
Takeda | Collaboration Agreement          
Licensing and other arrangements          
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       16,000  
Revenue from contracts with customers $ 2,000        
Contract assets       0 0
Contract liabilities       0 0
Capitalized contract costs       0 0
Takeda | Collaboration Agreement | TAK-079          
Licensing and other arrangements          
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   $ 19,000      
Royalty payment period   13 years 6 months      
Revenue from contracts with customers       800  
Takeda | Collaboration Agreement | Other antibodies          
Licensing and other arrangements          
Maximum eligible milestone payments receivable per discovery product candidate     $ 3,300    
Royalty payment period     10 years    
Takeda | Collaboration Agreement | License          
Licensing and other arrangements          
Revenue from contracts with customers       $ 100 $ 100